Barriers to clinical trial enrollment

Part I of a two-part series

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

According to the National Cancer Institute (NCI), 1,735,350 people were newly diagnosed with cancer in 2018. Of those, 65% are expected to achieve remission from their cancer 1.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
Daniel Wall, BSc
Research administrator, Marshfield Clinic
Stephanie Engelien, RN, MSN
Oncology research nurse, Marshfield Clinic
Adedayo A. Onitilo, MD, PhD, MSCR, FACP
Director, Oncology/Hematology
and Radiation Oncology Service Line; Department chair, Oncology/Hematology, Marshfield Clinic

Login